Remus Pharmaceuticals Income Statement

Financials in millions INR. Fiscal year is April - March.

Millions INR. Fiscal year is Apr - Mar.

Fiscal Year	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Mar '26 Mar 31, 2026	Mar '25 Mar 31, 2025	Mar '24 Mar 31, 2024	Mar '23 Mar 31, 2023	Mar '22 Mar 31, 2022
Operating Revenue	8,536	6,204	2,129	450.27	247.17
Other Revenue	66.9	-	-	1.05	-
Revenue	8,603	6,204	2,129	451.32	247.17
Revenue Growth (YoY)	38.68%	191.33%	371.81%	82.59%	31.42%
Cost of Revenue	7,422	5,330	1,635	214.69	122.81
Gross Profit	1,181	873.9	494.6	236.63	124.36
Selling, General & Admin	128.2	131.1	73.2	54.7	34.24
Other Operating Expenses	419.2	285.9	131.8	70.45	46.32
Operating Expenses	575	435.7	216.2	129.92	82.1
Operating Income	606.1	438.2	278.4	106.71	42.26
Interest Expense	-14.7	-14.6	-5	-2.04	-0.78
Interest & Investment Income	-	29	22.5	3.48	2.45
Currency Exchange Gain (Loss)	-	9.8	5.6	6.24	2.22
Other Non Operating Income (Expenses)	0.2	8.9	0.1	-0.26	-0.09
EBT Excluding Unusual Items	591.6	471.3	301.6	114.14	46.06
Gain (Loss) on Sale of Investments	-	-	-	-	0.08
Gain (Loss) on Sale of Assets	-	2.1	-	-	-
Pretax Income	591.6	473.4	301.6	114.14	46.13
Income Tax Expense	129.9	89.2	58.9	29.11	11.79
Earnings From Continuing Operations	461.7	384.2	242.7	85.03	34.34
Minority Interest in Earnings	-91.8	-93.5	-37.5	-	-
Net Income	369.9	290.7	205.2	85.03	34.34
Net Income to Common	369.9	290.7	205.2	85.03	34.34
Net Income Growth	27.25%	41.67%	141.33%	147.60%	234.77%
Shares Outstanding (Basic)	9	12	11	8	8
Shares Outstanding (Diluted)	9	12	11	8	8
Shares Change (YoY)	-19.90%	4.28%	38.35%	2.10%	-
EPS (Basic)	39.19	24.67	18.16	10.41	4.29
EPS (Diluted)	39.19	24.67	18.16	10.41	4.29
EPS Growth	58.86%	35.85%	74.43%	142.51%	234.77%
Free Cash Flow	35.9	30	-19.4	25.81	49.67
Free Cash Flow Per Share	3.80	2.55	-1.72	3.16	6.21
Dividend Per Share	-	0.750	0.750	0.250	-
Dividend Growth	-	-	200.00%	-	-
Gross Margin	13.73%	14.09%	23.23%	52.43%	50.31%
Operating Margin	7.04%	7.06%	13.07%	23.64%	17.10%
Profit Margin	4.30%	4.69%	9.64%	18.84%	13.89%
Free Cash Flow Margin	0.42%	0.48%	-0.91%	5.72%	20.09%
EBITDA	633.7	450.1	287.2	111.36	43.81
EBITDA Margin	7.37%	7.26%	13.49%	24.67%	17.72%
D&A For EBITDA	27.6	11.9	8.8	4.64	1.55
EBIT	606.1	438.2	278.4	106.71	42.26
EBIT Margin	7.04%	7.06%	13.07%	23.64%	17.10%
Effective Tax Rate	21.96%	18.84%	19.53%	25.50%	25.56%
Revenue as Reported	8,603	6,253	2,158	466.05	254.37

Source: S&P Global Market Intelligence. Standard template. Financial Sources.